58
Participants
Start Date
December 7, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
May 31, 2028
Enfortumab vedotin
Given into the bladder (intravesically)
COMPLETED
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RECRUITING
Sidney Kimmel Cancer Center, Philadelphia
RECRUITING
Johns Hopkins Medical Center, Baltimore
COMPLETED
Duke University Medical Center, Durham
RECRUITING
Site ES34002, Madrid
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Site FR33003, Rennes
RECRUITING
Site DE49001, Göttingen
RECRUITING
Erlanger Oncology and Hematology, Chattanooga
RECRUITING
Markey Cancer Center / University of Kentucky, Lexington
RECRUITING
James Cancer Hospital / Ohio State University, Columbus
RECRUITING
Northwestern University-Feinberg School of Medicine, Chicago
RECRUITING
Rush University Medical Center, Chicago
RECRUITING
Site FR33002, Lyon
RECRUITING
Site DE49002, Tübingen
RECRUITING
Site FR33001, Paris
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
MD Anderson, Houston
RECRUITING
Urology San Antonio, San Antonio
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
Mayo Clinic, Scottsdale
RECRUITING
UCLA Department of Medicine - Hematology & Oncology, Los Angeles
RECRUITING
University of California, Irvine, Orange
RECRUITING
University of California at San Francisco, San Francisco
RECRUITING
Stanford Health Care, Stanford
RECRUITING
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Site CA11001, Toronto
RECRUITING
Site ES34001, Barcelona
RECRUITING
Site ES34004, Barcelona
RECRUITING
Site ES34003, Barcelona
RECRUITING
Site UK44002, London
Seagen, a wholly owned subsidiary of Pfizer
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY